Adaptive Two‐Stage Designs for Single‐Arm Phase IIA Cancer Clinical Trials

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Biometrics

• Publication date

  2004-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/j.0006-341X.2004.00193.xPMID 15180674
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Bayesian two‐stage designs for phase II clinical trials by S. B. Tan and D. Machin, Statistics in Medicine 2002; 21:1991–2012

  2006cited by this paper
• On changing a long‐term clinical trial midstream

  2002cited by this paper
• Bayesian two‐stage designs for phase II clinical trials

  2002cited by this paper
• Optimal two-stage designs for single arm Phase II cancer trials

  2002cited by this paper
• Sample Size Reestimation in Clinical Trials

  2001cited by this paper
• Graphical search for two-stage designs for phase II clinical trials.

  2001cited by this paper
• Sample size re‐estimation – journey for a decade

  2001cited by this paper
• Internal pilot studies II: comparison of various procedures.

  1999cited by this paper
• A design alternative for two-stage, phase II, multicenter cancer clinical trials.

  1998cited by this paper
• Modifying the design of ongoing trials without unblinding.

  1998cited by this paper
• Design for sample size re-estimation with interim data for double-blind clinical trials with binary outcomes.

  1997cited by this paper
• Optimal three-stage designs for phase II cancer clinical trials.

  1997influential reference
• Planned versus attained design in phase II clinical trials.

  1992cited by this paper
• Research Methods in Clinical Oncology

  1989cited by this paper
• Optimal two-stage designs for phase II clinical trials.

  1989influential reference
• The determinatio of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent.

  1961cited by this paper

• Stopping rules for phase II clinical trials: an overview

  2025cites this paper
• Efficient Study Designs for the Early-Stage Evaluation of Disease-Modifying Treatments in Parkinson Disease.

  2025cites this paper
• M-DODII: Bayesian dose optimization design for randomized phase II study with multiple indications.

  2025cites this paper
• Adaptive sample size re-estimation designs for a two-stage randomized trial with binary outcome

  2025cites this paper
• BOP2-FE: Bayesian optimal phase II design with futility and efficacy-stopping boundaries.

  2025cites this paper
• BOP2-Comb: Bayesian Optimal Phase II Design for Optimizing Doses and Assessing Contribution of Components in Drug Combinations

  2025cites this paper
• Two-Stage Design Sample Size Determination for Two Doses in Oncology Phase II Trials

  2025cites this paper
• Phase I/II Study of Subasumstat (TAK-981) in Combination With Rituximab in Relapsed/Refractory Non-Hodgkin Lymphoma.

  2025cites this paper
• Adaptive sequential design for phase II single-arm oncology trials: an expansion of Simon’s design

  2024cites this paper
• BUPD: A Bayesian under-parameterized basket design with the unit information prior in oncology trials

  2024cites this paper
• Bayesian Methods for Information Borrowing in Basket Trials: An Overview

  2024cites this paper
• Evolution of Phase II Oncology Trial Design: from Single Arm to Master Protocol

  2023cites this paper
• A Bayesian adaptive biomarker stratified phase II randomized clinical trial design for radiotherapies with competing risk survival outcomes

  2023cites this paper
• DODII: Bayesian Dose Optimization Design for Randomized Phase II Trials

  2023cites this paper
• Nature-inspired Metaheuristics for finding Optimal Designs for the Continuation-Ratio Models

  2023cites this paper
• Two-stage response adaptive randomization designs for multi-arm trials with binary outcome

  2023cites this paper
• Promising zone two-stage design for a single-arm study with binary outcome

  2023cites this paper
• Bayesian order constrained adaptive design for phase II clinical trials evaluating subgroup-specific treatment effect

  2023cites this paper
• Modified Simon’s Two-Stage Design for Phase IIA Clinical Trials in Oncology—Dynamic Monitoring and More Flexibility

  2023cites this paper
• Spatial two-stage designs for phase II clinical trials

  2022cites this paper
• Evaluation of two-stage designs of Phase 2 single-arm trials in glioblastoma: a systematic review

  2022cites this paper
• A multicenter phase 2 trial of camrelizumab plus famitinib for women with recurrent or metastatic cervical squamous cell carcinoma

  2022cites this paper
• An Overview of Adaptive Designs and Some of Their Challenges, Benefits, and Innovative Applications

  2022cites this paper
• Camrelizumab plus famitinib for advanced or metastatic urothelial carcinoma after platinum-based therapy: data from a multicohort phase 2 study

  2022cites this paper
• A Bayesian Precision Response-adaptive Phase II Clinical Trial Design for Radiotherapies with Competing Risk Survival Outcomes

  2022cites this paper
• Antitumor activity and safety of camrelizumab plus famitinib in patients with platinum-resistant recurrent ovarian cancer: results from an open-label, multicenter phase 2 basket study

  2022cites this paper
• Opportunity for efficiency in clinical development: An overview of adaptive clinical trial designs and innovative machine learning tools, with examples from the cardiovascular field.

  2021cites this paper
• Stopping for efficacy in single-arm phase II clinical trials

  2021influential citation
• Phase II Studies in Oncology : Current Practices of Choosing Group Configuration and Statistical Design

  2021cites this paper
• Modelling approaches for histology-independent cancer drugs to inform NICE appraisals: a systematic review and decision-framework.

  2021cites this paper
• Practical and robust test for comparing binomial proportions in the randomized phase II setting

  2021cites this paper
• Camrelizumab plus Famitinib in Patients with Advanced or Metastatic Renal Cell Carcinoma: Data from an Open-label, Multicenter Phase II Basket Study

  2021cites this paper
• A Bayesian hierarchical monitoring design for phase II cancer clinical trials: Incorporating information on response duration into monitoring rules

  2021cites this paper
• Bayesian phase II clinical trial design with noncompliance

  2021cites this paper
• BILITE: A Bayesian randomized phase II design for immunotherapy by jointly modeling the longitudinal immune response and time‐to‐event efficacy

  2020cites this paper
• Bayesian enhancement two‐stage design with error control for phase II clinical trials

  2020cites this paper
• A Comparative Study on the SWOG Two-Stage Design Extension to Stop Early for Efficacy in Single Arm Phase II Trials

  2020cites this paper
• RoBoT: a robust Bayesian hypothesis testing method for basket trials.

  2020cites this paper
• Modified Simon’s minimax and optimal two-stage designs for single-arm phase II cancer clinical trials

  2019cites this paper
• Bayesian predictive monitoring with bivariate binary outcomes in phase II clinical trials

  2019cites this paper
• On construction of single‐arm two‐stage designs with consideration of both response and toxicity

  2019cites this paper
• Biostatistical and Logistical Considerations in the Development of Basket and Umbrella Clinical Trials

  2019cites this paper
• Adaptive two-stage optimal designs for phase II clinical studies that allow early futility stopping

  2019cites this paper
• BRAF Inhibition in BRAFV600-Mutant Gliomas: Results From the VE-BASKET Study

  2018cites this paper
• Extended two-stage adaptive designs with three target responses for phase II clinical trials

  2018cites this paper
• Interval and point estimation in adaptive Phase II trials with binary endpoint

  2018cites this paper
• Reasonable two‐stage adaptive designs for single‐arm phase II clinical trials

  2018cites this paper
• Bayesian Designs: Phase II Oncology Clinical Trials

  2018cites this paper
• Bias and precision in early phase adaptive oncology studies and its consequences for confirmatory trials

  2018cites this paper
• Point estimation and p‐values in phase II adaptive two‐stage designs with a binary endpoint

  2017cites this paper
• Vemurafenib for BRAF V600–Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Analysis of Data From the Histology-Independent, Phase 2, Open-label VE-BASKET Study

  2017cites this paper
• An efficient basket trial design

  2017cites this paper
• Efficient confidence limits for adaptive one-arm two-stage clinical trials with binary endpoints

  2017cites this paper
• MIDAS: a practical Bayesian design for platform trials with molecularly targeted agents

  2016cites this paper
• Optimal adaptive two‐stage designs for early phase II clinical trials

  2016cites this paper
• Accounting for uncertainty in the historical response rate of the standard treatment in single‐arm two‐stage designs based on Bayesian power functions

  2016cites this paper
• Adaptive designs for Phase II oncology trials

  2015cites this paper
• Performance of Adaptive Designs for Single-Armed Phase II Oncology Trials

  2015cites this paper
• Bayesian sequential monitoring design for two‐arm randomized clinical trials with noncompliance

  2015cites this paper
• Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.

  2015cites this paper
• A Bayesian design for phase II clinical trials with delayed responses based on multiple imputation

  2014cites this paper
• Optimal Designs for Two-Arm Randomized Phase II Clinical Trials with Multiple Constraints

  2014cites this paper
• Lessons learned from lung cancer genomics: the emerging concept of individualized diagnostics and treatment.

  2013cites this paper
• Optimal adaptive two‐stage designs for phase II cancer clinical trials

  2013influential citation
• Biomarkeranalytik aus Sicht des Pathologen

  2013cites this paper
• Improving the Flexibility and Efficiency of Phase II Designs for Oncology Trials

  2012cites this paper
• Statistical Designs for Early Phases of Cancer Clinical Trials

  2012cites this paper
• A Free Gift: An Adaptive Strategy in a Single-Arm Trial Using an Exact Test Through the Binomial Distribution

  2012influential citation
• A Bayesian–frequentist two‐stage single‐arm phase II clinical trial design

  2012cites this paper
• Adaptive designs for single‐arm phase II trials in oncology

  2012cites this paper
• Simon's Minimax and Optimal and Jung's Admissible Two-stage Designs with or without Curtailment

  2011cites this paper
• On Simon's two‐stage design for single‐arm phase IIA cancer clinical trials under Beta‐binomial distribution

  2010influential citation
• A Bayesian predictive strategy for an adaptive two‐stage design in phase II clinical trials

  2010cites this paper
• Design of adaptive two-stage double-arm clinical trials for dichotomous variables.

  2010cites this paper
• A STUDY OF STAGEWISE PHASE II AND PHASE II/III DESIGNS FOR CLINICAL TRIALS

  2010cites this paper
• Two-stage designs optimal under the alternative hypothesis for phase II cancer clinical trials

  2010cites this paper
• Two-Stage Sample Size Reassessment Using Perturbed Unblinding

  2009cites this paper
• Approaches to handling data when a phase II trial deviates from the pre‐specified Simon's two‐stage design

  2008cites this paper
• 17 Early Phase Clinical Trials: Phases I and II

  2007cites this paper
• Using SAS® to Determine Sample Sizes for Traditional 2-Stage and Adaptive 2-Stage Phase II Cancer Clinical Trial Designs

  2007cites this paper
• Group sequential, sample size re‐estimation and two‐stage adaptive designs in clinical trials: a comparison

  2006cites this paper
• Optimizing the ongoing search for new treatments for Parkinson disease

  2006cites this paper
• Rational drug sequencing of paclitaxel, gemcitabine and carboplatin in patients with untreated stage IV and select stage IIIB non-small cell lung cancer.

  2006cites this paper
• How Practical are Adaptive Designs Likely to be for Confirmatory Trials?

  2006cites this paper
• Effect of docetaxel in patients with hormone-dependent prostate-specific antigen progression after local therapy for prostate cancer.

  2005cites this paper